Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)

The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.

NCT Number	NCT07511569
Lead Sponsor	Centre Hospitalier de Bligny Collaborators: Hopital Forcilles, AgenT
Conditions	Chemotherapy Induced Neuropathic Pain, Neuropathy Toxic, Taxane-induced Peripheral Neuropathy, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
Enrollment	192 participants
Start Date	2027-01-04
Primary Completion	2029-01-04 (estimated)
Study Completion	2029-06-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-13